Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures

American Journal of Neuroradiology

Volumn 33, Issue 7, 2012, Pages 1211-1220

  Hussein, Haitham M ^a   Georgiadis, A L ^a   Qureshi, A I ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ARGATROBAN; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; PLACEBO; TIROFIBAN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; DRUG EFFECT; DRUG HALF LIFE; ENDOVASCULAR SURGERY; HUMAN; NEUROENDOVASCULAR PROCEDURE; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; REVIEW;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; HUMANS; NEUROSURGICAL PROCEDURES; POINT-OF-CARE SYSTEMS; PREMEDICATION; THROMBOSIS; VASCULAR SURGICAL PROCEDURES;

EID: 84865304079     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2621     Document Type: Review

References (90)

1. Riedel CH, Tietke M, Alfke K, et al. Subacute stent thrombosis in intracranial stenting. Stroke 2009;40:1310-14
2. Ries T, Buhk JH, Kucinski T, et al. Intravenous administration of acetylsalicylic acid during endovascular treatment of cerebral aneurysms reduces the rate of thromboembolic events. Stroke 2006;37:1816-21
3. Qureshi AI, Luft AR, Sharma M, et al. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures. Part II. Clinical aspects and recommendations. Neurosurgery 2000;46:1360-75, discussion 75-76
4. Krpski WC, Bass A, Kelly AB, et al. Heparin-resistant thrombus formation by endovascular stents in baboons: interruption by a synthetic antithrombin. Circulation 1990;82:570-77
5. Chaer RA, Graham JA, Mureebe L. Platelet function and pharmacologic inhibition. Vasc Endovascular Surg 2006;40:261-67
6. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 suppl):141S-59S
7. Laux V, Perzborn E, Heitmeier S, et al. Direct inhibitors of coagulation proteins: the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 2009;102:892-99
8. SoRelle R. 1999 Bristol-Myers Squibb cardiovascular metabolic research award: Earl Davie, PhD, defined the system of blood coagulation. Circulation 1999;100:332
9. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-17
10. El Rouby S, Cohen M, Gonzales A, et al. The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures. J Thromb Thrombolysis 2006;21:137-45
11. Saw J, Kereiakes DJ, Mahaffey KW, et al. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb Res 2003;112:301-06
12. Toschi V, Lettino M, Gallo R, et al. Biochemistry and biology of hirudin. Coron Artery Dis 1996;7:420-28
13. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008, 99:830-39
14. Witting JI, Bourdon P, Maraganore JM, et al. Hirulog-1 and -B2 thrombin specificity. Biochem J 1992;287(pt 2):663-64
15. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-59
16. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143:847-53
17. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63
18. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16
19. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30
20. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29
21. Chia S, Van Cott EM, Raffel OC, et al. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation. Thromb Haemost 2009;101:535-40
22. van Putten J, van de Ruit M, Beunis M, et al. Automated determination of heparin with chromogenic substrates. Haemostasis 1984;14:184-94
23. Tietz NW, ed. Clinical guide to laboratory tests. Philadelphia: W. B. Saunders Company; 1995:228-29
24. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966;196:436-40
25. Van Cott EM. Point-of-care testing in coagulation. Clin Lab Med 2009;29:543-53
26. Feindt P, Seyfert UT, Volkmer I, et al. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy. Thorac Cardiovasc Surg 1994;42:218-21
27. Andrew M, MacIntyre B, MacMillan J, et al. Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. Thromb Haemost 1993;70:937-41
28. Marmur JD, Bullock-Palmer RP, Poludasu S, et al. Avoiding intelligence failures in the cardiac catheterization laboratory: strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention. J Invasive Cardiol 2009;21:653-64
29. Lawrence M, Mixon TA, Cross D, et al. Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention. Catheter Cardiovasc Interv 2004;61:52-55
30. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Col Cardiol 2003;41:394-402
31. Dougherty KG, Gaos CM, Bush HS, et al. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 1992;26:260-63
32. Zahn R, Haubelt H, Bechtloff S, et al. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Herz 2003;28:445-52
33. American Association for Clinical Chemistry. Laboratory Medicine Practice Guidelines. 2007: www.aacc.org/members/nacb/LMPG/OnlineGuide/ PublishedGuidelines/poct/Pages/poctpdf.aspx. Accessed December 2010
34. Shimada YJ, Nakra NC, Fox JT, et al. Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention. Am J Cardiol 2010;105:629-32
35. Pesola GR, Johnson A, Pesola DA. Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time. Cathet Cardiovasc Diagn 1996;37:140-44
36. Spinler SA, Wittkowsky AK, Nutescu EA, et al. Anticoagulation monitoring. Part 2. Unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother 2005;39:1275-85
37. Proceedings of the seventh ACCP conference on antithrombotic and thrombolytic therapy: Evidence-based guidelines. Chest 2004;126:172S-696S
38. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-65
39. Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-71
40. Pinto DS, Lorenz DP, Murphy SA, et al. Association of an activated clotting time < or = 250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TAC TICS-TIMI 18 substudy). Am J Cardiol 2003;91:976 -78, A4
41. Montalescot G, Cohen M, Salette G, et al. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J 2008;29:462-71
42. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001;103:961-66
43. Brener SJ, Bhatt DL, Moliterno DJ, et al. Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. Am J Cardiol 2003;92:1468-71
44. Bertrand OF, Rodes-Cabau J, Rinfret S, et al. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy. Am J Cardiol 2009;104:1235-40
45. Schumacher HC, Meyers PM, Higashida RT, et al. Reporting standards for angioplasty and stent-assisted angioplasty for intracranial atherosclerosis. Stroke 2009;40:e348-65
46. Jiang WJ, Wang YJ, Du B, et al. Stenting of symptomatic M1 stenosis of middle cerebral artery: an initial experience of 40 patients. Stroke 2004;35:1375-80
47. Henkes H, Miloslavski E, Lowens S, et al. Treatment of intracranial atherosclerotic stenoses with balloon dilatation and self-expanding stent deployment (WingSpan). Neuroradiology 2005;47:222-28
48. Lylyk P, Cohen JE, Ceratto R, et al. Angioplasty and stent placement in intracranial atherosclerotic stenoses and dissections. AJNR Am J Neuroradiol 2002;23:430-36
49. Levy EI, Boulos AS, Guterman LR. Stent-assisted endoluminal revascularization for the treatment of intracranial atherosclerotic disease. Neurol Res 2002;24:337-46
50. Castellan L, Causin F, Danieli D, et al. Carotid stenting with filter protection: correlation of ACT values with angiographic and histopathologic findings. J Neuroradiol 2003;30:103-08
51. Yokote H, Terada T, Ryujin K, et al. Percutaneous transluminal angioplasty for intracranial arteriosclerotic lesions. Neuroradiology 1998;40:590-96
52. Qureshi AI, Suri MF, Siddiqui AM, et al. Clinical and angiographic results of dilatation procedures for symptomatic intracranial atherosclerotic disease. J Neuroimaging 2005;15:240-49
53. Gress DR, Smith WS, Dowd CF, et al. Angioplasty for intracranial symptomatic vertebrobasilar ischemia. Neurosurgery 2002;51:23-27, discussion 27-29
54. Saw J, Bajzer C, Casserly IP, et al. Evaluating the optimal activated clotting time during carotid artery stenting. Am J Cardiol 2006;97:1657-60
55. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;351:1493-501
56. Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010;363:11-23. Epub 2010 May 26
57. Cavusoglu E, Lakhani M, Marmur JD. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. J Invasive Cardiol 2005;17:416-21
58. Marmur JD, Lakhani M, El Rouby S, et al. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory. J Invasive Cardiol 2008;20:449-54
59. Silvain J, Beygui F, Ankri A, et al. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. J Am Coll Cardiol 2010;55:617-25
60. Casserly IP, Topol EJ, Jia G, et al. Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes: observations from the TARGET trial. Am J Cardiol 2003; 92:125-29
61. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial): evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559-62
62. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614-17
63. Dauerman HL, Ball SA, Goldberg RJ, et al. Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention. J Thromb Thrombolysis. 2002;13:127-32
64. Furman MI, Krueger LA, Frelinger AL 3rd, et al. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000;84:492-98
65. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166-286
66. Tolleson TR, O'Shea JC, Bittl JA, et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 2003;41:386-93
67. Hemochron [package insert]. http://www.itcmed.com/Products 2010
68. Pan C-M, Jobes D, Van Riper D, et al. A modified microsample ACT test for heparin monitoring. J Extra Corpor Technol 1996;28:16-20
69. Despotis GJ, Joist JH, Hogue CW Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46-54
70. Jaryno SA, Zucker ML, LaDuca FM. The Hemochron Response RxDx heparin and protamine dosing system. J Extra Corpor Technol 2004;36:258-62
71. Shore-Lesserson L, Reich DL, DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth 1998;45:10-18
72. Silvain J, Beygui F, Ankri A, et al. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. J Am Coll Cardiol 2010;55:617-25
73. Medtronic; Minneapolis, Minnesota. http://www.medtronic.com/for-health care-professionals/products-therapies/cardiovascular/therapies/perfusion/index. htm#tab2. Accessed December 2010
74. Despotis GJ, Alsoufiev AL, Spitznagel E, et al. Response of kaolin act to haparin: Evaluation with an automated assay and higher heparin doses. Annal Thoracic Surg 1996;61:795-99
75. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-xa heparin concentration in patients having cardiac operations. J Thoracic Cardiovasc Surg 1994;108:1076-82
76. Garvin S, Fitzgerald DC, Despotis G, et al. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg 2010;111:849-55. Epub 2009 Oct 27
77. Gravlee G, Davis R, Stammers A, et al. Cardiopulmonary Bypass: Principles and Practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008
78. Owings JT, Pollock ME, Gosselin RC, et al. Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques. Arch Surg 2000;135:1042-47
79. Helft G, Bartolomeo P, Zaman AG, et al. The heparin management test: a new device for monitoring anticoagulation during coronary intervention. Thrombosis Res 1999;96:481-85
80. Tsimikas S, Beyer R, Hassankhani A. Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention. J Thromb Thrombolysis 2001;11:217-21
81. Ganter MT, Dalbert S, Graves K, et al. Monitoring activated clotting time for combined heparin and aprotinin application: an in vitro evaluation of a new aprotinin-insensitive test using SONOCLOT. Anesth Analg 2005;101:308-14
82. Ganter MT, Monn A, Tavakoli R, et al. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Eur J Cardiothorac Surg 2006;30:278-84
83. Paniccia R, Fedi S, Carbonetto F, et al. Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings: the i-STAT celite-activated clotting time test. Anesthesiology 2003;99:54-59
84. Bosch YP, Ganushchak YM, de Jong DS. Comparison of ACT point-of-care measurements: repeatability and agreement. Perfusion 2006;21:27-31
85. Espana F, Ratnoff OD. Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med 1983;102:31-45
86. Leyvi G, Shore-Lesserson L, Harrington D, et al. An investigation of a new activated clotting time "MAX-ACT" in patients undergoing extracorporeal circulation. Anesth Analg 2001;92:578-83
87. Prisco D, Paniccia R. Point-of-care testing of hemostasis in cardiac surgery. Thromb J 2003;1:1
88. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008;106:1366-75
89. Wang JS, Lin CY, Hung WT, et al. Thromboelastogram fails to predict postoperative hemorrhage in cardiac patients. Ann Thorac Surg 1992;53:435-39
90. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005;27:81-90